
In the phase 1a–1b Beamion LUNG-1 trial, zongertinib, an oral HER2-selective TKI, demonstrated a 71% objective response rate in previously treated HER2-mutant NSCLC (cohort 1), with a median response duration of 14.1 months. Efficacy was observed across cohorts, with low incidence of grade ≥3 adverse events and no interstitial lung disease. Zongertinib offers promise as an effective, tolerable option in HER2-mutant NSCLC.
Like
Save
Share